Clinical and laboratory parameters predicting a requirement for the reevaluation of growth hormone status during growth hormone treatment: Retesting early in the course of GH treatment. (June 2017)

• Record Type: Journal Article
• Authors: Vuralli, Dogus; Gonc, E. Nazli; Ozon, Z. Alev; Alikasifoglu, Ayfer; Kandemir, Nurgun
• Is Part Of: Growth hormone & IGF research. Volume 34(2017)
• Page Start: 31
• Page End: 37
• Publication Date: 2017-06
• Subjects: Growth hormone -- Growth disorders -- Hypopituitarism -- Pituitary function tests -- Pituitary gland; Growth regulators -- Periodicals; Growth -- Regulation -- Periodicals; Somatomedin -- Periodicals; Somatomedins -- Periodicals; Growth Hormone -- Periodicals; Growth Substances -- Periodicals; Croissance -- Régulation -- Périodiques; Croissance -- Régulateurs -- Périodiques; Somatotrophine -- Périodiques; Somatomédine -- Périodiques; Growth -- Regulation; Growth regulators; Electronic journals; Periodicals; Electronic journals; 612.4
• DOI: 10.1016/j.ghir.2017.05.003
• Languages: English
• ISSNs: 1096-6374

Abstract

Abstract: Objective: We aimed to define the predictive criteria, in the form of specific clinical, hormonal and radiological parameters, for children with growth hormone deficiency (GHD) who may benefit from the reevaluation of GH status early in the course of growth hormone (GH) treatment. Design and Methods: Two hundred sixty-five children with growth hormone deficiency were retested by GH stimulation at the end of the first year of GH treatment. The initial clinical and laboratory characteristics of those with a normal (GH ≥ 10 ng/ml) response and those with a subnormal (GH < 10 ng/ml) response were compared to predict a normal GH status during reassessment. Results: Sixty-nine patients (40.6%) out of the 170 patients with isolated growth hormone deficiency (IGHD) had a peak GH of ≥ 10 ng/ml during the retest. None of the patients with multiple pituitary hormone deficiency (MPHD) had a peak GH of ≥ 10 ng/ml. Puberty and sex steroid priming in peripubertal cases increased the probability of a normal GH response. Only one patient with IGHD who had an ectopic posterior pituitary without stalk interruption on MRI analysis showed a normal GH response during the retest. Patients with a peak GH between 5 and 10 ng/ml, an age at diagnosis of ≥ 9 years or a height gain below 0.61 SDS during the first year of treatment had an increased probability of having a normal GH response at the retest. Conclusion: Early reassessment of GH status during GH treatment is unnecessary in patients who have MPHD with at least 3 hormone deficiencies. Retesting at the end of the first year of therapy is recommended for patients with IGHD who have a height gain of < 0.61 SDS in the first year of treatment, especially those with a normal or 'hypoplastic' pituitary on imaging. Priming can increase the likelihood of a normal response in patients in the pubertal age group who do not show overt signs of pubertal development. Highlights: Forty percent of patients with IGHD had a peak GH of ≥ 10 ng/ml at retest. None of the patients with MPHD had a peak GH of ≥ 10 ng/ml at retest. Retesting is unnecessary in patients with MPHD with at least 3 hormone deficiencies. Patients with IGHD who have normal/hypoplastic pituitary may benefit from retesting. Priming can increase the likelihood of normal response in peripubertal age group.